Exercise for patients with low-risk myeloid cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the feasibility and safety of an exercise intervention for patients diagnosed with low-risk myelodysplastic syndrome or clonal cytopenia of undetermined significance. The aim is to determine if exercise can serve as an early intervention to potentially prevent progression to more severe hematological cancers. Participants will be assessed for their ability to engage in physical activity, and those who meet the criteria will undergo an exercise regimen while being monitored for safety and effectiveness. The study is conducted at Rigshospitalet in Denmark.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* A diagnosis of either Lower-risk of Myelodysplastic Syndrome or Clonal Cytopenia of undetermined significance(WHO 2022 Classification)
* Written informed consent prior to study procedures
* Performance status ≤ 2
* Age \> 18 years old

Exclusion Criteria:

* Physically not able to undergo exercise intervention (e.g., arthrosis, physical disabilities)
* Exercising on a regular basis (i.e., participants must score in the category "low" when screening with International Physical Activity Questionnaire-Short Form; IPAQ-SF27)
* Unwillingness to undergo exercise intervention
* Use of metformin
* Treatment with chemotherapy, therapeutic radiation, or immunosuppressive therapy within the last year
* Treatment with hypomethylating agents
* Any absolute contraindication to undergo cardiopulmonary exercise testing according to working papers from American Heart Association and Danish Society of Cardiology
* Hemoglobin levels \< 5.5 mmol OR \<6.5 mmol and simultaneous cardiac insufficiency OR pacemaker.
* Blood transfusion-dependent ≥ 8 units of red blood cell transfusion in 16 weeks (IWG 2018-criteria)
* Uncontrolled co-morbidity

Where it's running

• Rigshospitalet
  Copenhagen, Denmark Recruiting
• Rigshospitalet
  Copenhagen, Denmark, Denmark Not yet recruiting

Study contacts

• Study coordinator: Kirsten Gørnbæk, Professor
• Email: kirsten.groenbaek@regionh.dk
• Phone: +4535456086

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Total marrow and lymphoid irradiation with fludarabine and melphalan for older adults with refractory/relapsed AML or high-risk MDS undergoing donor stem cell transplant

  This phase 2 trial tests a targeted radiation conditioning (TMLI) with fludarabine and melphalan before a matched donor stem cell transplant in people aged 50 or older with difficult-to-treat AML or high-risk MDS.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07582172

• Nicotinamide Riboside and Pterostilbene in lower risk MDS and high-risk CCUS

  This phase 2 study tests whether nicotinamide riboside plus pterostilbene can help improve blood counts in adults with lower risk MDS or high-risk CCUS who are not transfusion-dependent.

  Recruiting Phase 2 University of Colorado, Denver · Aurora, Colorado · NCT07579429

• QUAIL-100 in kids and young adults after stem cell transplant with high-risk blood cancers

  This study tests QUAIL-100 in pediatric and young adult patients who have high-risk acute leukemia or myelodysplastic syndrome and have already received a partially matched stem cell transplant.

  Recruiting Phase 1 Laguna Biotherapeutics, Inc. · Palo Alto, California · NCT07573111

• Elritercept versus epoetin alfa for transfusion-dependent anemia in lower-risk MDS

  This study tests whether elritercept can reduce the need for red blood cell transfusions and improve fatigue compared with epoetin alfa in adults with very low-, low-, or intermediate-risk myelodysplastic syndromes who need regular transfusions.

  Recruiting at 103 sites Phase 3 Takeda · Gilbert, Arizona and 165 other locations · NCT07422480

• CD64 CAR T Therapy for Adults with Relapsed or Refractory AML

  This phase 1 study tests a patient’s own CD64-directed CAR T cells to see if they can be safely given and potentially help adults with relapsed or refractory AML.

  Recruiting Phase 1 University of Colorado, Denver · Aurora, Colorado · NCT07347418

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.